DK1047428T3 - Anvendelse af morpholinol til behandlingen af seksualforstyrrelser - Google Patents

Anvendelse af morpholinol til behandlingen af seksualforstyrrelser

Info

Publication number
DK1047428T3
DK1047428T3 DK99903200T DK99903200T DK1047428T3 DK 1047428 T3 DK1047428 T3 DK 1047428T3 DK 99903200 T DK99903200 T DK 99903200T DK 99903200 T DK99903200 T DK 99903200T DK 1047428 T3 DK1047428 T3 DK 1047428T3
Authority
DK
Denmark
Prior art keywords
morpholinol
treatment
sexual disorders
sexual
disorders
Prior art date
Application number
DK99903200T
Other languages
Danish (da)
English (en)
Inventor
Phillip Frederick Morgan
David Lee Musso
John Joseph Partridge
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1047428T3 publication Critical patent/DK1047428T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99903200T 1998-01-21 1999-01-20 Anvendelse af morpholinol til behandlingen af seksualforstyrrelser DK1047428T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9801230.5A GB9801230D0 (en) 1998-01-21 1998-01-21 Pharmaceutically active morpholinol
US7218098P 1998-01-22 1998-01-22
PCT/US1999/001134 WO1999037305A1 (en) 1998-01-21 1999-01-20 Pharmaceutically active morpholinol

Publications (1)

Publication Number Publication Date
DK1047428T3 true DK1047428T3 (da) 2007-10-08

Family

ID=26312986

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99903200T DK1047428T3 (da) 1998-01-21 1999-01-20 Anvendelse af morpholinol til behandlingen af seksualforstyrrelser

Country Status (30)

Country Link
US (2) US6274579B1 (zh)
EP (2) EP1829544A1 (zh)
JP (1) JP2002501025A (zh)
KR (1) KR100568063B1 (zh)
CN (2) CN1255389C (zh)
AP (1) AP1229A (zh)
AT (1) ATE365042T1 (zh)
AU (1) AU755536B2 (zh)
BR (1) BR9907203A (zh)
CA (1) CA2318268A1 (zh)
CY (1) CY1106828T1 (zh)
DE (1) DE69936335T2 (zh)
DK (1) DK1047428T3 (zh)
EA (1) EA002410B1 (zh)
EE (1) EE04452B1 (zh)
ES (1) ES2288012T3 (zh)
HR (2) HRP20000494B1 (zh)
HU (1) HUP0100900A3 (zh)
ID (1) ID26334A (zh)
IL (2) IL161942A0 (zh)
IS (1) IS2494B (zh)
NO (2) NO326878B1 (zh)
NZ (3) NZ529316A (zh)
PL (1) PL193622B1 (zh)
PT (1) PT1047428E (zh)
SG (1) SG115489A1 (zh)
SK (1) SK10912000A3 (zh)
TR (1) TR200002126T2 (zh)
WO (1) WO1999037305A1 (zh)
YU (1) YU67102A (zh)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) * 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
AU2349999A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmacological uses of pure (+) -bupropion
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
AU7750100A (en) * 1999-10-13 2001-04-23 Glaxo Group Limited Method for the treatment of obesity
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US7145649B2 (en) * 2000-12-21 2006-12-05 Brasscorp Limited Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en) 2001-12-31 2005-12-27 R.J. Doran & Co. LTD LED inspection lamp
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
MXPA04011203A (es) 2002-05-17 2005-07-14 Univ Duke Metodo para tratar la obesidad.
US7384941B2 (en) * 2002-08-23 2008-06-10 Eli Lilly And Company 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
EP2316456B1 (en) 2003-04-29 2017-06-14 Orexigen Therapeutics, Inc. Compositions for affecting weight loss comprising an opioid antagonist and bupropion
JP2007509855A (ja) * 2003-10-27 2007-04-19 スミスクライン ビーチャム コーポレーション （＋）−（２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノール、その塩および溶媒和物を調製するためのジアステレオマー動的速度論分割プロセス
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
GB0327619D0 (en) * 2003-11-27 2003-12-31 Smithkline Beecham Corp New use
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
CA2553207A1 (en) * 2004-01-13 2005-08-04 Kishore M. Gadde Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
JP2007536229A (ja) * 2004-05-03 2007-12-13 デューク・ユニバーシティー 体重減少に作用するための組成物
FI117283B (fi) 2005-02-04 2006-08-31 Kone Corp Hissijärjestelmä
WO2007067341A2 (en) 2005-11-22 2007-06-14 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US7763612B2 (en) * 2006-01-03 2010-07-27 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR101479324B1 (ko) 2006-11-09 2015-01-05 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
MX343867B (es) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CA2758774C (en) 2009-04-15 2015-02-03 Research Triangle Institute Monoamine reuptake inhibitors
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
JP5952267B2 (ja) 2010-05-21 2016-07-13 リサーチ・トライアングル・インスティチュート 薬物依存を処置するためのヒドロキシブプロピオン類似体（政府支援研究または開発）
CA2800220C (en) 2010-05-21 2019-04-30 Research Triangle Institute Phenylmorpholines and analogues thereof
US9510405B2 (en) 2011-06-30 2016-11-29 Schneider Electric Industries Sas Dual power SMPS for a modular lighting system
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
AU2013271622B2 (en) 2012-06-06 2018-03-01 Nalpropion Pharmaceuticals Llc Methods of treating overweight and obesity
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) * 2021-06-17 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US170430A (en) * 1875-11-30 Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) * 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
GB9108629D0 (en) 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use

Also Published As

Publication number Publication date
KR20010034285A (ko) 2001-04-25
YU67102A (sh) 2004-12-31
AU755536B2 (en) 2002-12-12
CA2318268A1 (en) 1999-07-29
IS2494B (is) 2009-02-15
PL193622B1 (pl) 2007-02-28
NO326878B1 (no) 2009-03-09
ATE365042T1 (de) 2007-07-15
CY1106828T1 (el) 2012-05-23
NO20003721D0 (no) 2000-07-20
EP1047428B1 (en) 2007-06-20
DE69936335T2 (de) 2008-02-28
HRP20000494B1 (en) 2009-02-28
NZ505809A (en) 2002-09-27
AU2328099A (en) 1999-08-09
CN1528753A (zh) 2004-09-15
IL137346A0 (en) 2001-07-24
US6391875B2 (en) 2002-05-21
CN1294513A (zh) 2001-05-09
NO20003721L (no) 2000-09-19
TR200002126T2 (tr) 2000-12-21
EA200000691A1 (ru) 2001-04-23
US6274579B1 (en) 2001-08-14
NZ529316A (en) 2004-05-28
PL342012A1 (en) 2001-05-07
IL161942A0 (en) 2005-11-20
SK10912000A3 (sk) 2001-04-09
ID26334A (id) 2000-12-14
EP1047428A1 (en) 2000-11-02
ES2288012T3 (es) 2007-12-16
AP1229A (en) 2003-12-04
EE200000438A (et) 2001-12-17
SG115489A1 (en) 2005-10-28
DE69936335D1 (de) 2007-08-02
HUP0100900A2 (hu) 2002-05-29
NO20083529L (no) 2000-09-19
HRP20051024A2 (hr) 2006-04-30
KR100568063B1 (ko) 2006-04-07
WO1999037305A1 (en) 1999-07-29
PT1047428E (pt) 2007-09-07
HRP20000494A2 (en) 2000-12-31
EE04452B1 (et) 2005-04-15
EP1829544A1 (en) 2007-09-05
US20020019396A1 (en) 2002-02-14
NZ520349A (en) 2004-02-27
IS5568A (is) 2000-07-20
CN1255389C (zh) 2006-05-10
CN1203858C (zh) 2005-06-01
EP1047428A4 (en) 2001-12-19
BR9907203A (pt) 2000-10-17
HUP0100900A3 (en) 2002-08-28
JP2002501025A (ja) 2002-01-15
AP2000001869A0 (en) 2000-09-30
EA002410B1 (ru) 2002-04-25

Similar Documents

Publication Publication Date Title
DK1047428T3 (da) Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DK0967214T3 (da) Intranasale formuleringer til behandling af seksuelle forstyrrelser
PT1446122E (pt) Utilizacao de flibanserina no tratamento de disturbios de desejo sexual
DK0966436T3 (da) Arylsulfonamider og analoger deraf og anvendelse deraf til behandling af neurodegenerative lidelser
DK1083889T3 (da) Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
DK1223927T3 (da) Anvendelse af retigabin til behandling af neuropatiske smerter
DK1604680T3 (da) Anvendelse af butulinumtoksin ved behandlingen af neuralgisk smerte
DE60020327D1 (de) Wasserbehandlungsvorrichtung
IS5921A (is) Staðgengnar Bensópýrahliðstæður til notkunar við meðhöndlun á bólgu
DK1021410T3 (da) Prostaglandinagonister og deres anvendelse til behandling af knogletilstande
DK1562932T3 (da) 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
ID30276A (id) Metode untuk mengobati gangguan-gangguan seksual
IS6137A (is) Meðhöndlun á hugsýkistruflunum
DK1345598T3 (da) Anvendelsen af rosiglitazon til behandling af psykiatriske lidelser
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
DK1257278T3 (da) Anvendelse af mirtazapin til behandling af sövnforstyrrelser
ID30458A (id) Osanetan dalam pengobatan gangguan jiwa
NO20010390D0 (no) Behandling av angstsykdommer
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
EE200200670A (et) S-metüüldihüdroziprasidoon psühhiaatriliste ja silmahaiguste raviks
DK1011678T3 (da) Anvendelse af mecamylamin til behandling af nikotin-responsive neuropsykiatriske lidelser
IS5324A (is) (S) 2-Metýlamínó-2-fenýl-n-bútýl 3,4,5-trímetoxý-bensóat, notkun þess til meðferðar á langvinnum sársauka
ATA89898A (de) Justierbare orthese